Clinical Trial Update: Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on adipose-derived mesenchymal stem cells for inducing remission in perianal fistulizing Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Adipose-derived mesenchymal stem cells

Snippet

Sponsor: Tigenix S.A.U. | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED